Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
IO Biotech
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Duke University
Seagen Inc.
Merck Sharp & Dohme LLC
Emory University
NeoImmuneTech
Merck Sharp & Dohme LLC
Ankara Etlik City Hospital
Merck Sharp & Dohme LLC
MedSIR
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Big Ten Cancer Research Consortium
Rutgers, The State University of New Jersey
Merck Sharp & Dohme LLC
Coherus Oncology, Inc.
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC
Dragonfly Therapeutics
University of Southern California
Hummingbird Bioscience
BerGenBio ASA
Tempest Therapeutics
Takeda
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
MacroGenics
Celgene
Yale University
Xencor, Inc.
Incyte Corporation
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
Bank of Cyprus Oncology Centre
Wake Forest University Health Sciences
Blanco, Dr Antonio Calles MD
University of Michigan Rogel Cancer Center
Mural Oncology, Inc
University of California, Davis